A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies

详细信息    查看全文

• 作者：Amy Jo Chien ; Alyson Cockerill ; Craig Fancourt…
• 关键词：HER2+ ; Akt ; inhibitor ; Breast cancer ; Trastuzumab resistance ; MK ; 2206
• 刊名：Breast Cancer Research and Treatment
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：155
• 期：3
• 页码：521-530
• 全文大小：878 KB
• 参考文献：1.Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD, Chodosh LA (2002) Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2(6):451–461CrossRef PubMed
  2.Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8(1):103–112PubMed
  3.Ram TG, Ethier SP (1996) Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ 7(5):551–561PubMed
  4.Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRef PubMed
  5.Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ (2007) Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7(5):389–397CrossRef PubMed
  6.Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50):7455–7464. doi:10.​1038/​sj.​onc.​1209085 CrossRef PubMed
  7.Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12):988–1004. doi:10.​1038/​nrd1902 CrossRef PubMed
  8.Steelman LS, Stadelman KM, Chappell WH, Horn S, Basecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA (2008) Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12(9):1139–1165. doi:10.​1517/​14728222.​12.​9.​1139 CrossRef PubMed
  9.Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700–5706. doi:10.​1200/​JCO.​2009.​23.​2025 PubMedCentral CrossRef PubMed
  10.Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672CrossRef PubMed
  11.Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684. doi:10.​1056/​NEJMoa052122 CrossRef PubMed
  12.Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792CrossRef PubMed
  13.Van Cutsem E, Kang Y, Chung H (2009) Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal groth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27(18s):abstract LBA4509
  14.Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62(14):4132–4141PubMed
  15.Clark AS, West K, Streicher S, Dennis PA (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1(9):707–717PubMed
  16.Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395–402. doi:10.​1016/​j.​ccr.​2007.​08.​030 CrossRef PubMed
  17.Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117–127CrossRef PubMed
  18.Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C, King TA (2012) Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 18(24):6784–6791. doi:10.​1158/​1078-0432.​CCR-12-1785 PubMedCentral CrossRef PubMed
  19.Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29(2):166–173. doi:10.​1200/​JCO.​2009.​27.​7814 PubMedCentral CrossRef PubMed
  20.Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177(4):1647–1656. doi:10.​2353/​ajpath.​2010.​090885 PubMedCentral CrossRef PubMed
  21.Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Diaz-Delgado MC, de la Pena L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J (2015) PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 33(12):1334–1339. doi:10.​1200/​JCO.​2014.​55.​2158 CrossRef PubMed
  22.Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445(7126):437–441. doi:10.​1038/​nature05474 PubMedCentral CrossRef PubMed
  23.She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3(8):e3065. doi:10.​1371/​journal.​pone.​0003065 PubMedCentral CrossRef PubMed
  24.Yap TA, Patnaik A, Fearen I, Olmos D, Papdopoulos K, Tunariu N (2010) First-in-class phase 1 trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. J Clin Oncol 28 (15s):(suppl; abstr 3009)
  25.Ji Y, Li Y, Nebiyou Bekele B (2007) Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 4(3):235–244. doi:10.​1177/​1740774507079442​ CrossRef PubMed
  26.Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F (2015) SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. doi:10.​1093/​jnci/​dju493 PubMedCentral PubMed
  27.Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van’t Veer LJ, Spellman PT, Gray JW (2013) Modeling precision treatment of breast cancer. Genome Biol 14(10):R110. doi:10.​1186/​gb-2013-14-10-r110 PubMedCentral CrossRef PubMed
  28.Han HS, Swanton C, Janjigian YY, Sutherland SC, Chandarlapaty S, Lehman R, Hamilton N, Knowles J, Lee R, Yan L, Sullivan D, Hudis C (2011) A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors. J Clin Oncol 29:(suppl; abstr 3028)
  29.Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS (2013) A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res 15(6):R110. doi:10.​1186/​bcr3577 PubMedCentral CrossRef PubMed
  30.Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688–4695. doi:10.​1200/​JCO.​2011.​35.​5263 CrossRef PubMed
  31.Tripathy DCA, Hylton N, Buxton MB, Ewing CA, Wallace AM, Forero A, Kaplan HG, Nanda R, Albain KS, Moulder SL, Haley BB, DeMichele A, Symmans WF, van ‘t Veer L, Paoloni M, Esserman L, Berry DA, Yee D (2015) Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. J Clin Oncol 33, 2015 (suppl; abstr 524)
  32.Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS (2015) Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res 21(4):739–748. doi:10.​1158/​1078-0432.​CCR-14-1901 PubMedCentral CrossRef PubMed
  33.Sathe A, Guerth F, Cronauer MV, Heck MM, Thalgott M, Gschwend JE, Retz M, Nawroth R (2014) Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer 111(11):2103–2113. doi:10.​1038/​bjc.​2014.​534 PubMedCentral CrossRef PubMed
  34.Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F (2012) Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 18(20):5816–5828. doi:10.​1158/​1078-0432.​CCR-12-1141 PubMedCentral CrossRef PubMed
  35.Sahlberg KK, Hongisto V, Edgren H, Makela R, Hellstrom K, Due EU, Moen Vollan HK, Sahlberg N, Wolf M, Borresen-Dale AL, Perala M, Kallioniemi O (2013) The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Mol Oncol 7(3):392–401. doi:10.​1016/​j.​molonc.​2012.​10.​012 CrossRef PubMed
  
• 作者单位：Amy Jo Chien (1)
  Alyson Cockerill (1)
  Craig Fancourt (2)
  Emmett Schmidt (3)
  Mark M. Moasser (1)
  Hope S. Rugo (1)
  Michelle E. Melisko (1)
  Andrew H. Ko (1)
  R. Katie Kelley (1)
  W. Michael Korn (1)
  Laura J. Esserman (4)
  Laura van‘t Veer (5)
  Christina Yau (4)
  Denise M. Wolf (5)
  Pamela N. Munster (1)
  
  1. Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA
  2. Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc, Kenilworth, NJ, USA
  3. Merck Research Laboratories, North Wales, PA, USA
  4. Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
  5. Department of Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Sanfrancisco, CA, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7217

文摘

Purpose Akt plays a key role in the aggressive pathogenesis of HER2+ malignancies, suggesting that Akt-inhibitors may be of therapeutic value in the treatment of HER2+ tumors. Preclinical studies demonstrate synergy between MK-2206, a selective allosteric Akt-inhibitor, with paclitaxel and trastuzumab. We aimed to evaluate the safety of this combination in patients with HER2+ malignancies.